suPAR is a Bad Omen for Chronic Kidney Disease Progression
Keywords:CKD , soluble- urokinase plasminogen activator receptor, creatinine, albumin creatinine ratio
The rationale for considering serum soluble- urokinase plasminogen activator receptor (s-uPAR) concentration as a potential biomarker for incipient CKD was primarily based on reports that increased levels of this receptor will serve as a circulating permeability variable that may be impaired at the start of FSGS and DN, a crucial explanation for CKD. So in early stages(1-3) of CKD, suPAR was evaluated. The aims of present paper are to investigate whether patients with CKD have distinct circulating suPAR, that could lead to a potential development of noninvasive diagnostic biomarkers of the disease. And finally using healthy subjects as a control group to determine specificity and sensitivity . 135 subjects were incorporated in this study, 30 were healthy control, with mean age 48.7±9.7years, and they were 14 males and 16 females. 105CKD patient , with mean age 50.1±10.0years, they were 54 males and 51 females. Blood samples were collected. Serum after centrifugation was isolated for estimation of suPAR by Enzyme linked immune sorbent assay , creatinine, and urea by enzymatic method . Early morning urine sample was collected to be used for determination albumin creatinine ratio in patient . suPAR level was higher in CKD patients than in healthy control, 6.179±2.221 versus 2.303±0.475, respectively; the difference was highly significant (P < 0.001) .To study the potential role of suPAR in diagnosis of patients with CKD, ROC showed that the cutoff value of suPAR was > 3.5 ng / ml fold shift with sensitivity and specificity; the AUC was 0.826 (95 % confidence interval: 0.690-0.920) and therefore 82.6 % precision and significance level of (P < 0.001). In conclusion, The suPAR is significantly more effective and also more comprehensive to CKD clinical assessment and can be supported with creatinine blood analysis.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions